Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection
Hepatitis B e antigen (HBeAg) is a widely used marker both for chronic hepatitis B (CHB) clinical management and HBV-related basic research. However, due to its high amino acid sequence homology to hepatitis B core antigen (HBcAg), most of available anti-HBe antibodies are cross-reactive with HBcAg...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2020.1862631 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850155981653147648 |
|---|---|
| author | Shao-Juan Wang Zi-Min Chen Min Wei Jia-Qi Liu Zong-Lin Li Tian-Shu Shi Sheng Nian Rao Fu Yang-Tao Wu Ya-Li Zhang Ying-Bin Wang Tian-Ying Zhang Jun Zhang Jun-Hui Xiong Shu-Ping Tong Sheng-Xiang Ge Quan Yuan Ning-Shao Xia |
| author_facet | Shao-Juan Wang Zi-Min Chen Min Wei Jia-Qi Liu Zong-Lin Li Tian-Shu Shi Sheng Nian Rao Fu Yang-Tao Wu Ya-Li Zhang Ying-Bin Wang Tian-Ying Zhang Jun Zhang Jun-Hui Xiong Shu-Ping Tong Sheng-Xiang Ge Quan Yuan Ning-Shao Xia |
| author_sort | Shao-Juan Wang |
| collection | DOAJ |
| description | Hepatitis B e antigen (HBeAg) is a widely used marker both for chronic hepatitis B (CHB) clinical management and HBV-related basic research. However, due to its high amino acid sequence homology to hepatitis B core antigen (HBcAg), most of available anti-HBe antibodies are cross-reactive with HBcAg resulting in high interference against accurate measurement of the status and level of HBeAg. In the study, we generated several monoclonal antibodies (mAbs) targeting various epitopes on HBeAg and HBcAg. Among these mAbs, a novel mAb 16D9, which recognizes the SKLCLG (aa −10 to −5) motif on the N-terminal residues of HBeAg that is absent on HBcAg, exhibited excellent detection sensitivity and specificity in pairing with another 14A7 mAb targeting the HBeAg C-terminus (STLPETTVVRRRGR, aa141 to 154). Based on these two mAbs, we developed a novel chemiluminescent HBeAg immunoassay (NTR-HBeAg) which could detect HBeAg derived from various HBV genotypes. In contrast to widely used commercial assays, the NTR-HBeAg completely eliminated the cross-reactivity with secreted HBcAg from precore mutant (G1896A) virus in either cell culture or patient sera. The improved specificity of the NTR-HBeAg assay enables its applicability in cccDNA-targeting drug screening in cell culture systems and also provides an accurate tool for clinical HBeAg detection. |
| format | Article |
| id | doaj-art-b4a0b51afac94f5aa4a5cce99d00325f |
| institution | OA Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-b4a0b51afac94f5aa4a5cce99d00325f2025-08-20T02:24:43ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512021-01-01101375010.1080/22221751.2020.1862631Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infectionShao-Juan Wang0Zi-Min Chen1Min Wei2Jia-Qi Liu3Zong-Lin Li4Tian-Shu Shi5Sheng Nian6Rao Fu7Yang-Tao Wu8Ya-Li Zhang9Ying-Bin Wang10Tian-Ying Zhang11Jun Zhang12Jun-Hui Xiong13Shu-Ping Tong14Sheng-Xiang Ge15Quan Yuan16Ning-Shao Xia17State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaXiamen Innodx Biotech Co., Ltd., Xiamen, People’s Republic of ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaXiamen Innodx Biotech Co., Ltd., Xiamen, People’s Republic of ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaNational Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Science, Xiamen University, Xiamen, People’s Republic of ChinaLiver Research Center, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, RI, USAState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, People’s Republic of ChinaHepatitis B e antigen (HBeAg) is a widely used marker both for chronic hepatitis B (CHB) clinical management and HBV-related basic research. However, due to its high amino acid sequence homology to hepatitis B core antigen (HBcAg), most of available anti-HBe antibodies are cross-reactive with HBcAg resulting in high interference against accurate measurement of the status and level of HBeAg. In the study, we generated several monoclonal antibodies (mAbs) targeting various epitopes on HBeAg and HBcAg. Among these mAbs, a novel mAb 16D9, which recognizes the SKLCLG (aa −10 to −5) motif on the N-terminal residues of HBeAg that is absent on HBcAg, exhibited excellent detection sensitivity and specificity in pairing with another 14A7 mAb targeting the HBeAg C-terminus (STLPETTVVRRRGR, aa141 to 154). Based on these two mAbs, we developed a novel chemiluminescent HBeAg immunoassay (NTR-HBeAg) which could detect HBeAg derived from various HBV genotypes. In contrast to widely used commercial assays, the NTR-HBeAg completely eliminated the cross-reactivity with secreted HBcAg from precore mutant (G1896A) virus in either cell culture or patient sera. The improved specificity of the NTR-HBeAg assay enables its applicability in cccDNA-targeting drug screening in cell culture systems and also provides an accurate tool for clinical HBeAg detection.https://www.tandfonline.com/doi/10.1080/22221751.2020.1862631Hepatitis B virusHepatitis B e antigenmonoclonal antibodycccDNA surrogateimmunoassay |
| spellingShingle | Shao-Juan Wang Zi-Min Chen Min Wei Jia-Qi Liu Zong-Lin Li Tian-Shu Shi Sheng Nian Rao Fu Yang-Tao Wu Ya-Li Zhang Ying-Bin Wang Tian-Ying Zhang Jun Zhang Jun-Hui Xiong Shu-Ping Tong Sheng-Xiang Ge Quan Yuan Ning-Shao Xia Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection Emerging Microbes and Infections Hepatitis B virus Hepatitis B e antigen monoclonal antibody cccDNA surrogate immunoassay |
| title | Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection |
| title_full | Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection |
| title_fullStr | Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection |
| title_full_unstemmed | Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection |
| title_short | Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection |
| title_sort | specific determination of hepatitis b e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis b virus infection |
| topic | Hepatitis B virus Hepatitis B e antigen monoclonal antibody cccDNA surrogate immunoassay |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2020.1862631 |
| work_keys_str_mv | AT shaojuanwang specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT ziminchen specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT minwei specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT jiaqiliu specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT zonglinli specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT tianshushi specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT shengnian specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT raofu specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT yangtaowu specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT yalizhang specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT yingbinwang specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT tianyingzhang specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT junzhang specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT junhuixiong specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT shupingtong specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT shengxiangge specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT quanyuan specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection AT ningshaoxia specificdeterminationofhepatitisbeantigenbyantibodiestargetingprecoreuniqueepitopefacilitatesclinicaldiagnosisanddrugevaluationagainsthepatitisbvirusinfection |